Identification of a peptide targeting CD56

Area of Science:

• Immunology
• Biochemistry
• Molecular Biology

Background:

• Neural cell adhesion molecule 1 (NCAM1/CD56) is a key marker on immune cells, myoblasts, and malignant cells.
• There is a growing need for CD56 detection and targeted therapies.
• Current methods often rely on antibody-based approaches.

Purpose of the Study:

• To develop a novel peptide ligand targeting human CD56.
• To evaluate the potential of this peptide for cell isolation and diagnosis.

Main Methods:

• T7 phage display technology was employed to discover the peptide ligand, named Natein.
• Natein's binding to the extracellular region of CD56 was confirmed.
• Cell isolation and tissue staining assays were performed using Natein.

Main Results:

• Natein successfully binds to natural killer (NK) cells and CD56-positive (CD56+) cancer cells.
• CD56+ cells were effectively enriched from peripheral blood mononuclear cells (PBMCs) using Natein-conjugated microbeads.
• Natein demonstrated comparable performance to CD56 antibodies in staining lymphoma tissues.

Conclusions:

• Natein is a novel peptide ligand that recognizes human CD56.
• Natein shows potential as a peptide-based alternative to CD56 antibodies for cell isolation and diagnosis.
• This peptide offers a promising tool for research and clinical applications involving CD56+ cells.